ѻý

Tirzepatide Fast-Tracked for Weight Loss; Geographical PCOS; New AID Guidelines

<ѻý class="mpt-content-deck">— News and commentary from the endocrinology world
MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

The FDA granted to the combination GIP/GLP-1 receptor agonist tirzepatide for overweight and obesity based on the SURMOUNT clinical program, Eli Lilly announced.

Across 13 countries, kids saw a stark rise in presenting with at diagnosis of type 1 diabetes during the pandemic. "This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents," the researchers wrote in Lancet Diabetes & Endocrinology.

Depending on where you live, (PCOS) may manifest differently. "Our study found geographical differences in PCOS in black and white women, suggesting there are both genetic and environmental influences on how this disease manifests," said Margareta Pisarska, MD, of Cedars-Sinai in Los Angeles, in a statement. (Journal of Clinical Endocrinology & Metabolism)

were both tied to decreased white matter integrity in the brain, according to data from the U.K. Biobank. (BMJ Open)

The American Diabetes Association and the European Association for the Study of Diabetes released a new consensus statement detailing everything clinicians should know about . (Diabetes Care)

may help keep people with diabetes out of the hospital and have better physical functioning. (Journal of the American Geriatrics Society)

Social determinants of health must also be tackled along with medical care in order to truly , researchers said in the New York Times.

No surprise here: moms who ate tended to have higher rates of overweight and obesity in their kids. (BMJ)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.